Epiomic Epidemiology Series: Autism Spectrum Disorders Forecast in 12 Major Markets 2015-2025

Date: 2015-09

Epidemiology Series Forecast Report on Autism Spectrum Disorders in 12 Major Markets
Autism Spectrum Disorders (ASD) or Pervasive Developmental Disorder (PDD) defines a group of developmental disability disorders. In this report, disorders include: Autism, Pervasive Developmental Disorder not otherwise specified (PDD-NOS) and Asperger Syndrome. Attributes of these disorders can be grouped into three areas: communication difficulties, repetitive and stereotyped behaviour and social impairment, with a wide variation of symptoms which can occur for any given patient.
This report provides the current prevalent population for ASD across 12 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Denmark, Sweden and China) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the type and severity of ASD, level of cognitive function and behavioural and motor dysfunction. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of ASD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for ASD include:
• Epilepsy
• Gastrointestinal problems
• Motor function/ co-ordination problems
• Anxiety
• Depression
• Hypotonia
• Restless Sleep
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global ASD’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of ASD and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on ASD’s prevalent population.
• Identify sub-populations within ASD which require treatment.
• Gain an understanding of the specific markets that have the largest number of ASD patients.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample